Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study

[1]  H. Mai,et al.  Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA. , 2021, European journal of cancer.

[2]  Wei Jiang,et al.  The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma , 2021, Cancer communications.

[3]  Ji-Jin Yao,et al.  Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma? , 2021, Journal of Cancer Research and Clinical Oncology.

[4]  Ji-Jin Yao,et al.  Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Yoshimi Anzai,et al.  Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  Xiang Guo,et al.  Clinical Implications of Plasma Epstein–Barr Virus DNA in Children and Adolescent Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy , 2020, Frontiers in Oncology.

[7]  Juan Wang,et al.  Comparison of long-term outcomes and sequelae between children and adult nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. , 2019, International journal of radiation oncology, biology, physics.

[8]  C. Qian,et al.  Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. , 2019, European journal of cancer.

[9]  Ying Sun,et al.  Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial , 2019, International journal of cancer.

[10]  Juan Wang,et al.  Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiation Therapy. , 2019, International journal of radiation oncology, biology, physics.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  Yong Su,et al.  Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[13]  Jun Ma,et al.  Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[14]  Xinping Zhang,et al.  Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Xiang Guo,et al.  A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma , 2017, Journal of Cancer Research and Clinical Oncology.

[16]  Ji-Jin Yao,et al.  Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? , 2017, Journal of Cancer.

[17]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[18]  Jun Ma,et al.  Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. , 2015, European Journal of Cancer.

[19]  H. Christiansen,et al.  Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults , 2012, Cancer.

[20]  A. Ferrari,et al.  A prospective protocol for nasopharyngeal carcinoma in children and adolescents , 2012, Cancer.

[21]  A. Ferrari,et al.  Differential features of nasopharyngeal carcinoma in children and adults: A SEER study , 2010, Pediatric blood & cancer.